CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

Marta Di Forti - Medical Cannabis Research Engine

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Marta Di Forti

OPENALEX: A5100701393↗ORCID: 0000-0002-3218-6925↗

Affiliations

Organizations

Apple (Israel)authorship · IL Centre for Mental Healthauthorship · GB King's College Londonauthorship · GB King's College - North Carolinaauthorship · US King's College Schoolauthorship · GB Kings Health Partnersauthorship · GB Klinik und Poliklinik für Psychiatrie und Psychotherapieauthorship · DE Mental Health Foundationauthorship · GB National Institute for Health and Care Researchauthorship · GB Neurosciences Instituteauthorship · US Psychiatry Research Trustauthorship · GB South London and Maudsley NHS Foundation Trustauthorship · GB University College Londonauthorship · GB University of Palermoauthorship · IT

Public evidence

31 connected articles

The rising tide of drug-induced psychosis.2026 · Europe PMC Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis.2026 · Europe PMC The impact of childhood trauma and cannabis use on paranoia: a structural equation model approach.2025 · Europe PMC Applying machine learning to international drug monitoring: classifying cannabis resin collected in Europe using cannabinoid concentrations.2025 · Europe PMC Are reasons for first using cannabis associated with subsequent cannabis consumption (standard THC units) and psychopathology?2025 · Europe PMC Methylomic signature of current cannabis use in two first-episode psychosis cohorts.2025 · Europe PMC Systematic review and meta-analysis on the effects of chronic peri-adolescent cannabinoid exposure on schizophrenia-like behaviour in rodents.2025 · Europe PMC The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.2024 · Europe PMC Cannabis use and cognitive biases in people with first-episode psychosis and their siblings.2024 · Europe PMC Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study.2024 · Europe PMC

Registered research

Connected studies

Testing the Efficacy of the Cannabis Clinic for Patients With Psychosis (CCP) Intervention for Cannabis Use Reduction/Cessation in Patients With First Episode Psychosisnct07245212

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

Cross-ancestry genetic investigation of schizophrenia, cannabis use disorder, and tobacco smoking.

2024 · Europe PMC

A proof-of-concept analysis of data from the first NHS clinic for young adults with comorbid cannabis use and psychotic disorders.2024 · Europe PMC

The Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study.2024 · Europe PMC

Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users2023 · PubMed Central Open Access

Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.2023 · Europe PMC

First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data2023 · PubMed Central Open Access

The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.2023 · Europe PMC

Cannabis use and psychotic disorders in diverse settings in the Global South: findings from INTREPID II.2023 · Europe PMC

Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank.2021 · PubMed Central Open Access

Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.2021 · PubMed Central Open Access

The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.2021 · PubMed Central Open Access

Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study.2021 · PubMed Central Open Access

Adverse effects of heavy cannabis use: even plants can harm the brain.2021 · PubMed Central Open Access

Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?2020 · PubMed Central Open Access

The Maudsley environmental risk score for psychosis.2020 · PubMed Central Open Access

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.2019 · PubMed Central Open Access

Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis.2017 · PubMed Central Open Access

Effect of high-potency cannabis on corpus callosum microstructure.2016 · Europe PMC

Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: a case-control study.2015 · PubMed Central Open Access

Role of Environmental Confounding in the Association between FKBP5 and First-Episode Psychosis2014 · PubMed Central Open Access